Mukul Agarwal Acquires 1.75 Per Cent Stake Worth Rs 27.9 Crore in Multibagger Women Specific Healthcare Company During Q4 FY25
The shares of the company have given 88 per cent returns in 12 months while in 5 years it has given multibagger returns of 2000 per cent.
Jagsonpal Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients. The company specializes in providing essential medicines focused on women-specific healthcare needs, primarily through the Gynaecology and Orthopaedics segments. Besides its core areas, JPL also operates across major therapeutic sub-segments including antibiotics, allergy management, immunity and cell protection, over-the-counter (OTC) products, dermatology, and pediatrics.
DSIJ's ‘Mid Bridge’ service recommends well researched Mid-Cap stocks for smart investing. If this interests you, download the service details here.
In the third quarter of the financial year 2025, JPL reported revenues of approximately Rs 74 crores, reflecting a fifty-seven per cent year-on-year growth. Net profit for the quarter surged 119 per cent year-on-year to RS 11.5 crores, resulting in a net profit margin of 15.5 per cent. Operating margins before ESOP cost expanded by 390 basis points to 22.9 per cent, while operating EBITDA for the YTD period stood at Rs 48 crores. Adjusted for the exceptional income from the Faridabad facility sale, the reported net profit reached Rs 49 crores.
Among key corporate developments, Jagsonpal Pharmaceuticals completed a stock split, changing the face value from Rs 5 to Rs 2. The company also divested its Faridabad facility for RS 41 crores, contributing an exceptional income of RS 23 crores during the quarter.
As of March 2025, the shareholding pattern stood as follows: promoters held 67.77 per cent, foreign institutional investors (FIIS) held 2.10 per cent, domestic institutional investors (DIIS) had no holding, and the public held 30.11 per cent. Ace investor Mukul Agarwal bought a 1.75 per cent stake in the company in Q4 FY25, valued at approximately Rs 27.9 crores, with a holding of 1,157,557 shares. The shares of the company have given 88 per cent returns in 12 months while in 5 years it has given multibagger returns of 2000 per cent
Investors should keep an eye on this Small-Cap stock.
Disclaimer: The article is for informational purposes only and not investment advice.